**Question:** Drugs used in the treatment of pruritus in PBC?

**Core Concept:** Pruritus is a common symptom in patients with Primary Biliary Cholangitis (PBC), a chronic liver disease characterized by the destruction of liver cells (hepatocytes) and subsequent damage to the bile ducts. Pruritus in PBC is usually secondary to the presence of elevated bile acids in the blood, which stimulate itch receptors in the skin.

**Why the Correct Answer is Right:**
Drugs used to treat pruritus in patients with PBC aim to decrease the levels of bile acids in the blood. Ursodeoxycholic acid (UDCA) is the first-line treatment, as it helps in reducing bilirubin levels, improving liver function tests, and reducing pruritus.

**Why Each Wrong Option is Incorrect:**
A. This option is incorrect because it does not target the primary cause of pruritus in PBC, which is elevated bile acids.
B. This option is incorrect as it is not specifically designed to address the elevated bile acid levels responsible for pruritus in PBC.
C. This option is incorrect because it does not address the primary cause of pruritus in PBC, which is elevated bile acids.
D. This option is incorrect as it is not specifically designed to address the elevated bile acid levels responsible for pruritus in PBC.

**Why the Correct Answer is Right:**
Drugs like cholestyramine, colestipol, or colesevelam are used as second-line treatments. These drugs are bile acid sequestrants, which bind to bile acids and reduce their reabsorption in the gut, leading to a decrease in circulating bile acids and, consequently, relief from pruritus in PBC patients.

**Why Each Wrong Option is Incorrect:**
A. Cholestyramine is incorrect because it is a third-line treatment, not suitable for severe pruritus in PBC.
B. Colestipol is incorrect as it is a third-line treatment, not suitable for severe pruritus in PBC patients.
C. Colesevelam is incorrect as it is a third-line treatment, not suitable for severe pruritus in PBC patients.

**Clinical Pearl:**
In patients with severe pruritus refractory to UDCA monotherapy, the use of bile acid sequestrants (cholestyramine, colestipol, or colesevelam) is considered. These drugs can help reduce circulating bile acids, alleviate pruritus, and improve liver function tests. However, it is essential to monitor lipid profile and electrolyte levels in these patients, as these medications may lead to hyperlipidemia and hypocalcemia.